Differential expression of oxidation-specific epitopes and apolipoprotein(a) in progressing and ruptured human coronary and carotid atherosclerotic lesions

Journal of Lipid Research

Volumn 53, Issue 12, 2012, Pages 2773-2790

  Van Dijk, Rogier A ^a   Kolodgie, Frank ^a   Ravandi, Amir ^b   Leibundgut, Gregor ^b   Hu, Patrick P ^b   Prasad, Anand ^b   Mahmud, Ehtisham ^b   Dennis, Edward ^c   Curtiss, Linda K ^d   Witztum, Joseph L ^b   Wasserman, Bruce A ^e   Otsuka, Fumiyuki ^a   Virmani, Renu ^a   Tsimikas, Sotirios ^b  

^a CVPATH INSTITUTE   (United States)

^b UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d SCRIPPS RESEARCH INSTITUTE   (United States)

^e JOHNS HOPKINS HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN; APOLIPOPROTEIN B100; EPITOPE; MALONALDEHYDE; PHOSPHOLIPID;

ADULT; ANTIBODY DETECTION; ARTICLE; CAROTID ATHEROSCLEROSIS; CAROTID ENDARTERECTOMY; CLINICAL ARTICLE; CORONARY ARTERY; CORONARY ARTERY ATHEROSCLEROSIS; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LIQUID CHROMATOGRAPHY; MACROPHAGE; MALE; MASS SPECTROMETRY; PRIORITY JOURNAL; SAPHENOUS VEIN; SAPHENOUS VEIN GRAFT;

APOLIPOPROTEINS A; ATHEROSCLEROSIS; BIOLOGICAL MARKERS; CAROTID ARTERY DISEASES; EPITOPES; FEMALE; HUMANS; MALE; MIDDLE AGED; OXIDATION-REDUCTION; PLAQUE, ATHEROSCLEROTIC;

EID: 84869074308     PISSN: 00222275     EISSN: 15397262     Source Type: Journal    
DOI: 10.1194/jlr.P030890     Document Type: Article

References (44)

1. Miller, Y. I., S. H. Choi, P. Wiesner, L. Fang, R. Harkewicz, K. Hartvigsen, A. Boullier, A. Gonen, C. J. Diehl, X. Que, et al. 2011. Oxidation-specific epitopes are danger-associated molecular patterns recognized by pattern recognition receptors of innate immunity. Circ. Res. 108: 235-248.
2. Chang, M. K., C. J. Binder, Y. I. Miller, G. Subbanagounder, G. J. Silverman, J. A. Berliner, and J. L. Witztum. 2004. Apoptotic cells with oxidation-specific epitopes are immunogenic and proinflammatory. J. Exp. Med. 200: 1359-1370.
3. Briley-Saebo, K. C., P. X. Shaw, W. J. Mulder, S. H. Choi, E. Vucic, J. G. Aguinaldo, J. L. Witztum, V. Fuster, S. Tsimikas, and Z. A. Fayad. 2008. Targeted molecular probes for imaging atherosclerotic lesions with magnetic resonance using antibodies that recognize oxidation-specific epitopes. Circulation. 117: 3206-3215.
4. Briley-Saebo, K. C., Y. S. Cho, P. X. Shaw, S. K. Ryu, V. Mani, S. Dickson, E. Izadmehr, S. Green, Z. A. Fayad, and S. Tsimikas. 2011. Targeted iron oxide particles for in vivo magnetic resonance detection of atherosclerotic lesions with antibodies directed to oxidation-specific epitopes. J. Am. Coll. Cardiol. 57: 337-347.
5. Briley-Saebo, K. C., T. H. Nguyen, A. M. Saeboe, Y. S. Cho, S. K. Ryu, E. R. Volkova, S. Dickson, G. Leibundgut, P. Wiesner, S. Green, et al. 2012. In vivo detection of oxidation-specific epitopes in atherosclerotic lesions using biocompatible manganese molecular magnetic imaging probes. J. Am. Coll. Cardiol. 59: 616-626.
6. Aikawa, M., S. Sugiyama, C. C. Hill, S. J. Voglic, E. Rabkin, Y. Fukumoto, F. J. Schoen, J. L. Witztum, and P. Libby. 2002. Lipid lowering reduces oxidative stress and endothelial cell activation in rabbit atheroma. Circulation. 106: 1390-1396.
7. Tsimikas, S., M. Aikawa, F. J. Miller, Jr., E. R. Miller, M. Torzewski, S. R. Lentz, C. Bergmark, D. D. Heistad, P. Libby, and J. L. Witztum. 2007. Increased plasma oxidized phospholipid:apolipoprotein B-100 ratio with concomitant depletion of oxidized phospholipids from atherosclerotic lesions after dietary lipid-lowering: a potential biomarker of early atherosclerosis regression. Arterioscler. Thromb. Vasc. Biol. 27: 175-181.
8. Torzewski, M., P. X. Shaw, K. R. Han, B. Shortal, K. J. Lackner, J. L. Witztum, W. Palinski, and S. Tsimikas. 2004. Reduced in vivo aortic uptake of radiolabeled oxidation-specific antibodies reflects changes in plaque composition consistent with plaque stabilization. Arterioscler. Thromb. Vasc. Biol. 24: 2307-2312.
9. Tsimikas, S., A. Miyanohara, K. Hartvigsen, E. Merki, P. X. Shaw, M. Y. Chou, J. Pattison, M. Torzewski, J. Sollors, T. Friedmann, et al. 2011. Human oxidation-specific antibodies reduce foam cell formation and atherosclerosis progression. J. Am. Coll. Cardiol. 58: 1715-1727.
10. Taleb, A., J. L. Witztum, and S. Tsimikas. 2011. Oxidized phospholipids on apolipoprotein B-100 (OxPL/apoB) containing lipoproteins: a biomarker predicting cardiovascular disease and cardiovascular events. Biomark. Med. 5: 673-694.
11. Schiopu, A., J. Bengtsson, I. Soderberg, S. Janciauskiene, S. Lindgren, M. P. S. Ares, P. K. Shah, R. Carlsson, J. Nilsson, and G. N. Fredrikson. 2004. Recombinant human antibodies against aldehyde-modified apolipoprotein B-100 peptide sequences inhibit atherosclerosis. Circulation. 110: 2047-2052.
12. Caligiuri, G., J. Khallou-Laschet, M. Vandaele, A. T. Gaston, S. Delignat, C. Mandet, H. V. Kohler, S. V. Kaveri, and A. Nicoletti. 2007. Phosphorylcholine-targeting immunization reduces atherosclerosis. J. Am. Coll. Cardiol. 50: 540-546.
13. Kramer, M. C., S. Z. Rittersma, R. J. de Winter, E. R. Ladich, D. R. Fowler, Y. H. Liang, R. Kutys, N. Carter-Monroe, F. D. Kolodgie, A. C. van der Wal, et al. 2010. Relationship of thrombus healing to underlying plaque morphology in sudden coronary death. J. Am. Coll. Cardiol. 55: 122-132.
14. Farb, A., D. K. Weber, F. D. Kolodgie, A. P. Burke, and R. Virmani. 2002. Morphological predictors of restenosis after coronary stenting in humans. Circulation. 105: 2974-2980.
15. Kolodgie, F. D., J. Narula, A. P. Burke, N. Haider, A. Farb, Y. Hui-Liang, J. Smialek, and R. Virmani. 2000. Localization of apoptotic macrophages at the site of plaque rupture in sudden coronary death. Am. J. Pathol. 157: 1259-1268.
16. Virmani, R., F. D. Kolodgie, A. P. Burke, A. Farb, and S. M. Schwartz. 2000. Lessons from sudden coronary death: a comprehensive morphological classification scheme for atherosclerotic lesions. Arterioscler. Thromb. Vasc. Biol. 20: 1262-1275.
17. Kolodgie, F. D., H. K. Gold, A. P. Burke, D. R. Fowler, H. S. Kruth, D. K. Weber, A. Farb, L. J. Guerrero, M. Hayase, R. Kutys, et al. 2003. Intraplaque hemorrhage and progression of coronary atheroma. N. Engl. J. Med. 349: 2316-2325.
18. Young, S. G., J. L. Witztum, D. C. Casal, L. K. Curtiss, and S. Bernstein. 1986. Conservation of the low density lipoprotein receptor- binding domain of apoprotein B. Demonstration by a new monoclonal antibody, MB47. Arteriosclerosis. 6: 178-188.
19. Boullier, A., P. Friedman, R. Harkewicz, K. Hartvigsen, S. R. Green, F. Almazan, E. A. Dennis, D. Steinberg, J. L. Witztum, and O. Quehenberger. 2005. Phosphocholine as a pattern recognition ligand for CD36. J. Lipid Res. 46: 969-976.
20. Friedman, P., S. Horkko, D. Steinberg, J. L. Witztum, and E. A. Dennis. 2002. Correlation of antiphospholipid antibody recognition with the structure of synthetic oxidized phospholipids. Importance of Schiff base formation and aldol condensation. J. Biol. Chem. 277: 7010-7020.
21. Tsimikas, S., W. Palinski, S. E. Halpern, D. W. Yeung, L. K. Curtiss, and J. L. Witztum. 1999. Radiolabeled MDA2, an oxidation-specific, monoclonal antibody, identifies native atherosclerotic lesions in vivo. J. Nucl. Cardiol. 6: 41-53.
22. Shaw, P. X., S. Horkko, S. Tsimikas, M. K. Chang, W. Palinski, G. J. Silverman, P. P. Chen, and J. L. Witztum. 2001. Human-derived anti-oxidized LDL autoantibody blocks uptake of oxidized LDL by macrophages and localizes to atherosclerotic lesions in vivo. Arterioscler. Thromb. Vasc. Biol. 21: 1333-1339.
23. Tsimikas, S., H. K. Lau, K. R. Han, B. Shortal, E. R. Miller, A. Segev, L. K. Curtiss, J. L. Witztum, and B. H. Strauss. 2004. Percutaneous coronary intervention results in acute increases in oxidized phospholipids and lipoprotein(a): short-term and long-term immunologic responses to oxidized low-density lipoprotein. Circulation. 109: 3164-3170.
24. Seimon, T. A., M. J. Nadolski, X. Liao, J. Magallon, M. Nguyen, N. T. Feric, M. L. Koschinsky, R. Harkewicz, J. L. Witztum, S. Tsimikas, et al. 2010. Atherogenic lipids and lipoproteins trigger CD36-TLR2-dependent apoptosis in macrophages undergoing endoplasmic reticulum stress. Cell Metab. 12: 467-482.
25. Berliner, J. A., N. Leitinger, and S. Tsimikas. 2009. The role of oxidized phospholipids in atherosclerosis. J. Lipid Res. 50 (Suppl) : S207-S212.
26. Podrez, E. A., E. Poliakov, Z. Shen, R. Zhang, Y. Deng, M. Sun, P. J. Finton, L. Shan, M. Febbraio, D. P. Hajjar, et al. 2002. A novel family of atherogenic oxidized phospholipids promotes macrophage foam cell formation via the scavenger receptor CD36 and is enriched in atherosclerotic lesions. J. Biol. Chem. 277: 38517-38523.
27. Shaw, P. X., S. Horkko, M. K. Chang, L. K. Curtiss, W. Palinski, G. J. Silverman, and J. L. Witztum. 2000. Natural antibodies with the T15 idiotype may act in atherosclerosis, apoptotic clearance, and protective immunity. J. Clin. Invest. 105: 1731-1740.
28. Tsimikas, S., B. P. Shortal, J. L. Witztum, and W. Palinski. 2000. In vivo uptake of radiolabeled MDA2, an oxidation-specific monoclonal antibody, provides an accurate measure of atherosclerotic lesions rich in oxidized LDL and is highly sensitive to their regression. Arterioscler. Thromb. Vasc. Biol. 20: 689-697.
29. Shao, B., S. Pennathur, I. Pagani, M. N. Oda, J. L. Witztum, J. F. Oram, and J. W. Heinecke. 2010. Modifying apolipoprotein A-I by malondialdehyde, but not by an array of other reactive carbonyls, blocks cholesterol efflux by the ABCA1 pathway. J. Biol. Chem. 285: 18473-18484.
30. Tsimikas, S., Z. Mallat, P. J. Talmud, J. J. Kastelein, N. J. Wareham, M. S. Sandhu, E. R. Miller, J. Benessiano, A. Tedgui, J. L. Witztum, et al. 2010. Oxidation-specific biomarkers, lipoprotein(a), and risk of fatal and nonfatal coronary events. J. Am. Coll. Cardiol. 56: 946-955.
31. Kiechl, S., J. Willeit, M. Mayr, B. Viehweider, M. Oberhollenzer, F. Kronenberg, C. J. Wiedermann, S. Oberthaler, Q. Xu, J. L. Witztum, et al. 2007. Oxidized phospholipids, lipoprotein(a), lipoprotein-associated phospholipase A2 activity, and 10-year cardiovascular outcomes: prospective results from the Bruneck study. Arterioscler. Thromb. Vasc. Biol. 27: 1788-1795.
32. Bergmark, C., A. Dewan, A. Orsoni, E. Merki, E. R. Miller, M. J. Shin, C. J. Binder, S. Horkko, R. M. Krauss, M. J. Chapman, et al. 2008. A novel function of lipoprotein [a] as a preferential carrier of oxidized phospholipids in human plasma. J. Lipid Res. 49: 2230-2239.
33. Rosenfeld, M. E., W. Palinski, S. Yla-Herttuala, S. Butler, and J. L. Witztum. 1990. Distribution of oxidation specific lipid-protein adducts and apolipoprotein B in atherosclerotic lesions of varying severity from WHHL rabbits. Arteriosclerosis. 10: 336-349.
34. Scanlon, C. E. O., B. Berger, G. Malcom, and R. W. Wissler. 1996. Evidence for more extensive deposits of epitopes of oxidized low density lipoprotein in aortas of young people with elevated serum thiocyanate levels. Atherosclerosis. 121: 23-33.
35. Weismann, D., K. Hartvigsen, N. Lauer, K. L. Bennett, H. P. Scholl, P. Charbel Issa, M. Cano, H. Brandstatter, S. Tsimikas, C. Skerka, et al. 2011. Complement factor H binds malondialdehyde epitopes and protects from oxidative stress. Nature. 478: 76-81.
36. Ravandi, A., S. M. Boekholdt, Z. Mallat, P. J. Talmud, J. J. Kastelein, N. J. Wareham, E. R. Miller, J. Benessiano, A. Tedgui, J. L. Witztum, et al. 2011. Relationship of IgG and IgM autoantibodies and immune complexes to oxidized LDL with markers of oxidation and inflammation and cardiovascular events: results from the EPICNorfolk Study. J. Lipid Res. 52: 1829-1836.
37. Tabas, I., K. J. Williams, and J. Boren. 2007. Subendothelial lipoprotein retention as the initiating process in atherosclerosis: update and therapeutic implications. Circulation. 116: 1832-1844.
38. Lundstam, U., E. Hurt-Camejo, G. Olsson, P. Sartipy, G. Camejo, and O. Wiklund. 1999. Proteoglycans contribution to association of Lp(a) and LDL with smooth muscle cell extracellular matrix. Arterioscler. Thromb. Vasc. Biol. 19: 1162-1167.
39. Dangas, G., J. A. Ambrose, D. J. D'Agate, J. H. Shao, S. Chockalingham, D. Levine, and D. A. Smith. 1999. Correlation of serum lipoprotein(a) with the angiographic and clinical presentation of coronary artery disease. Am. J. Cardiol. 83: 583-585, A7.
40. Clarke, R., J. F. Peden, J. C. Hopewell, T. Kyriakou, A. Goel, S. C. Heath, S. Parish, S. Barlera, M. G. Franzosi, S. Rust, et al. 2009. Genetic variants associated with Lp(a) lipoprotein level and coronary disease. N. Engl. J. Med. 361: 2518-2528.
41. Kamstrup, P. R., A. Tybjaerg-Hansen, R. Steffensen, and B. G. Nordestgaard. 2009. Genetically elevated lipoprotein(a) and increased risk of myocardial infarction. JAMA. 301: 2331-2339.
42. Merki, E., M. J. Graham, A. E. Mullick, E. R. Miller, R. M. Crooke, R. E. Pitas, J. L. Witztum, and S. Tsimikas. 2008. Antisense oligonucleotide directed to human apolipoprotein B-100 reduces lipoprotein(a) levels and oxidized phospholipids on human apolipoprotein B-100 particles in lipoprotein(a) transgenic mice. Circulation. 118: 743-753.
43. Cannon, C. P., S. Shah, H. M. Dansky, M. Davidson, E. A. Brinton, A. M. Gotto, M. Stepanavage, S. X. Liu, P. Gibbons, T. B. Ashraf, et al. 2010. Safety of anacetrapib in patients with or at high risk for coronary heart disease. N. Engl. J. Med. 363: 2406-2415.
44. Raal, F. J., R. D. Santos, D. J. Blom, A. D. Marais, M. J. Charng, W. C. Cromwell, R. H. Lachmann, D. Gaudet, J. L. Tan, S. Chasan-Taber, et al. 2010. Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised, double-blind, placebo-controlled trial. Lancet. 375: 998-1006